Article: A De-Novo drug design and ADMET study to design small molecule stabilisers targeting mutant (V210I) human prion protein against familial Creutzfeldt-Jakob disease (fCJD) Journal: International Journal of Computational Biology and Drug Design (IJCBDD) 2020 Vol.13 No.1 pp.21 - 35 Abstract: The purpose of our project was to computationally design small molecule stabilisers targeting mutant (V210I) human prion protein (HuPrP) using combined De-novo pharmacophore based drug design and virtual molecular docking. The newly designed molecules were also analysed so it might qualify as a new cure for the familial Creutzfeldt-Jakob disease (fCJD). We collected the target protein structure from protein data bank (RCSB PDB). and minimised the energy using Yasara energy minimisation webserver and validated the structure using RAMPAGE webserver. We used KV Finder, a plug-in of Pymol to identify the drug binding pockets in the target protein. The pocket information was used for de-novo ligand design using the e-LEA3D webserver. Those ligands were used to generate a pharmacophore using LigandScout for the selected pockets. The pharmacophores were used as the search templates using Pharmit for the virtual screening of small molecules from Pubchem database followed by the docking of the screened small molecules in the pockets using Autodock Vina. Best five molecules were selected for ADMET properties using SwissADME. All the five small molecules were proven to be the ideal candidates for further drug development. Inderscience Publishers - linking academia, business and industry through research

Title: A De-Novo drug design and ADMET study to design small molecule stabilisers targeting mutant (V210I) human prion protein against familial Creutzfeldt-Jakob disease (fCJD)

Authors: Rafat Alam; G.M. Sayedur Rahman; Nahid Hasan; Abu Sayeed Chowdhury

Addresses: Department of Pharmaceutical Sciences, North South University, Bashundhara, Dhaka, 1229, Bangladesh ' Department of Pharmaceutical Sciences, North South University, Bashundhara, Dhaka, 1229, Bangladesh ' Department of Pharmaceutical Sciences, North South University, Bashundhara, Dhaka, 1229, Bangladesh ' Department of Pharmaceutical Sciences, North South University, Bashundhara, Dhaka, 1229, Bangladesh

Abstract: The purpose of our project was to computationally design small molecule stabilisers targeting mutant (V210I) human prion protein (HuPrP) using combined De-novo pharmacophore based drug design and virtual molecular docking. The newly designed molecules were also analysed so it might qualify as a new cure for the familial Creutzfeldt-Jakob disease (fCJD). We collected the target protein structure from protein data bank (RCSB PDB). and minimised the energy using Yasara energy minimisation webserver and validated the structure using RAMPAGE webserver. We used KV Finder, a plug-in of Pymol to identify the drug binding pockets in the target protein. The pocket information was used for de-novo ligand design using the e-LEA3D webserver. Those ligands were used to generate a pharmacophore using LigandScout for the selected pockets. The pharmacophores were used as the search templates using Pharmit for the virtual screening of small molecules from Pubchem database followed by the docking of the screened small molecules in the pockets using Autodock Vina. Best five molecules were selected for ADMET properties using SwissADME. All the five small molecules were proven to be the ideal candidates for further drug development.

Keywords: ADMET; absorption; distribution; metabolism; excretion; toxicity; de-novo drug design; docking; prion; PDB; pharmacophore.

DOI: 10.1504/IJCBDD.2020.105103

International Journal of Computational Biology and Drug Design, 2020 Vol.13 No.1, pp.21 - 35

Received: 06 Sep 2018
Accepted: 29 Nov 2018
Published online: 13 Feb 2020 *

Full-text access for editors Full-text access for subscribers Purchase this article Comment on this article

Title: A De-Novo drug design and ADMET study to design small molecule stabilisers targeting mutant (V210I) human prion protein against familial Creutzfeldt-Jakob disease (fCJD)

Keep up-to-date